Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status
The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosciences’ TYRA-300 for treating achondroplasia.
The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosciences’ TYRA-300 for treating achondroplasia.
What's Your Reaction?
